BGM Group (BGM) vs Cellectis S.A. (CLLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed BGM Group (BGM) over the past year, losing 70.9% versus a loss of 96.6%. Over five years, CLLS leads with a -88.5% price change compared with -98.3% for BGM. BGM Group is the larger company by market cap ($133.0 million vs $125.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | CLLS |
|---|---|---|
| Share price | $9.96 | $1.25 |
| Market cap | $133.01M | $125.90M |
| 1-day change | +6.07% | -6.72% |
| YTD return | -91.00% | -74.17% |
| 1-year return | -96.64% | -70.93% |
| 5-year return | -98.32% | -88.46% |
| EPS (TTM) | $-4.80 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $5.48 |
| 52-week low | $6.45 | $1.22 |
| Distance from 52-week high | -96.71% | -77.19% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +326.40% |
| Average volume | 6.13K | 78.59K |
| Shares outstanding | 12.69M | 72.72M |
| Employees | — | 224 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLLS has outperformed BGM by 25.7 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
BGM vs CLLS FAQ
Which is bigger, BGM Group or Cellectis S.A.?
BGM Group (BGM) is larger, with a market capitalization of $133.01M compared with $125.90M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, BGM or CLLS?
CLLS returned -70.93% over the past 12 months, compared with -96.64% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Cellectis S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.